The CHMP issued a positive opinion recommending the approval of bimekizumab for the treatment of PsA and axSpA in EU. Marketing approvals expected within 2 months.TP and Buy rating maintained, while waiting for the FDA's decision regarding the marketing approval applications for bimekizumab in psoriasis and Roza in gMG in the US, in the coming week.
